Charles River Laboratories International, Inc. (CRL)
$
158.48
+1.50 (0.95%)
Key metrics
Financial statements
Free cash flow per share
11.7702
Market cap
7.8 Billion
Price to sales ratio
1.9360
Debt to equity
0.8308
Current ratio
1.3604
Income quality
-12.1369
Average inventory
284.9 Million
ROE
-0.0201
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Charles River Laboratories International, Inc. is a prominent non-clinical contract research organization that offers a range of services, including drug discovery, non-clinical development, and safety testing across various global markets, including the United States, Europe, Canada, and the Asia Pacific. The cost of revenue for the company is $2,718,168,000.00 showcasing its production and operational expenses that support its comprehensive service offerings. With an operating income ratio of 0.06 the company's operational profitability margin reflects its ability to maintain efficiency in its business activities. Additionally, the company incurred an interest expense of $126,288,000.00 which indicates its debt servicing obligations and financial commitments. The total costs and expenses for the company amount to $3,822,642,000.00 reflecting its overall spending in pursuit of excellence in research services. Furthermore, the gross profit ratio is 0.33 which assesses the efficiency of the company's production and sales operations, underscoring its strategic management practices and financial health. Moving forward, the stock is reasonably priced at $158.04 appealing to a broad range of investors seeking opportunities in the market. The stock has an average trading volume of 885,454.00 indicating moderate liquidity, which is favorable for both institutional and retail investors. With a mid-range market capitalization of $7,799,466,416.00 the company is recognized as a steady performer within the competitive landscape. It is a key player in the Medical - Diagnostics & Research industry, contributing significantly to the overall market landscape through its innovative approaches and extensive portfolio of services. Moreover, it belongs to the Healthcare sector, driving innovation and growth that enhance its reputation and stability in the industry as it responds to evolving market needs.
Is Charles River Laboratories International, Inc. (CRL) a good investment?
Investing in Charles River Laboratories International, Inc. (CRL) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bearish outlook. Always conduct your own research before investing.
What is Charles River Laboratories International, Inc. (CRL)'s stock forecast?
Analysts predict Charles River Laboratories International, Inc. stock to fluctuate between $91.86 (low) and $230.02 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Charles River Laboratories International, Inc.'s market capitalization?
As of 2025-08-20, Charles River Laboratories International, Inc.'s market cap is $7,799,466,416, based on 49,214,200 outstanding shares.
How does Charles River Laboratories International, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Charles River Laboratories International, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Charles River Laboratories International, Inc. (CRL) stock?
To buy Charles River Laboratories International, Inc. (CRL) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CRL. Place an order (Market, Limit, etc.).
What is the best time to invest in Charles River Laboratories International, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Charles River Laboratories International, Inc. perform in the last earnings report?
Revenue: $4,049,989,000 | EPS: $0.20 | Growth: -97.84%.
Where can I find Charles River Laboratories International, Inc.'s investor relations reports?
Visit https://www.criver.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Charles River Laboratories International, Inc.?
You can explore historical data from here
What is the all-time high and low for Charles River Laboratories International, Inc. stock?
All-time high: $460.21 (2021-09-24) | All-time low: $91.86 (2025-04-11).
What are the key trends affecting Charles River Laboratories International, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Charles River Laboratories International, Inc. (NYSE:CRL ) Q2 2025 Earnings Conference Call August 6, 2025 9:00 AM ET Company Participants Flavia H. Pease - Corporate Executive VP & CFO James C.
seekingalpha.com
Charles River Laboratories posted a strong Q2 beat, but results were boosted by one-time items and cost cuts that may not be sustainable. Ongoing risks include regulatory pressure to phase out animal testing and weak organic revenue growth, especially in the Discovery and Safety Assessment segment. Management raised full-year guidance, but H2 faces margin and revenue headwinds; Q3 EPS is expected to decline sequentially.
zacks.com
Charles River Laboratories (CRL) came out with quarterly earnings of $3.12 per share, beating the Zacks Consensus Estimate of $2.5 per share. This compares to earnings of $2.8 per share a year ago.
zacks.com
CRL gears up for Q2 earnings with expected revenue and EPS declines amid mixed segment performance.
zacks.com
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
zacks.com
CRL sees momentum in drug discovery and safety services, but macro pressures and currency headwinds threaten growth.
proactiveinvestors.co.uk
Shares in Creightons PLC (LSE:CRL) dropped 10% on Wednesday despite reporting a return to profitability, as investors reacted to a cautious outlook for the year ahead. The beauty and personal care manufacturer posted a 1.6% rise in revenue to £54.1 million for the year to 31 March 2025, with strong growth in private label sales offsetting declines in branded and contract manufacturing.
zacks.com
RARE faces regulatory setback as FDA issues a CRL for UX111, delaying approval of the MPS IIIA gene therapy until 2026.
zacks.com
Charles River (CRL) reported earnings 30 days ago. What's next for the stock?
zacks.com
CRL and CHDI Foundation extend their Huntington's disease partnership, boosting integration and global flexibility in drug discovery.
See all news
